CCL18 and Autoimmunity: The safety and lack of autoimmunity secondary to CD4-AsiC knockdown of PITPNM3 or antibody inhibition of CCL18, PITPNM3 or CCR8 will need to be examined carefully to evaluate potential therapeutic applications.